We report a study of seven children with recurrent stage IV neuroblastoma comparing the uptake pattern of 123I-metaiodobenzylguanidine (mIBG) with 99mTc-labeled monoclonal antibody (MAb) BW 575 by the tumor lesions. Immunofluorescence studies of bone marrow had verified specific binding of the antibody to the tumor cells. The majority of tumor sites was detected both by mIBG and MAb scans. However, five of 26 lesions were not detected by mIBG and eight of 26 were false negative by immunoscintigraphy. The false negative lesions by mIBG belonged to five different patients (one of five primary, four of five bone marrow). In conclusion, MAb BW 575 may detect mIBG-negative neuroblastoma sites. The presence of antibody-negative sites suggests the utilization of both scintigraphy methods together.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00043426-199021000-00011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Eur J Haematol
November 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, Massachusetts, USA.
Objectives: Cluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi-centre, Phase 1, single-agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)-modified anti-CD38 monoclonal antibody (mAb), with enhanced affinity towards Fc-gamma receptor on effector cells in patients with relapsed and/or refractory (RR) MM.
Methods: This study comprised two parts: Part-A (dose-escalation involving anti-CD38 mAb pre-treated and naïve patients) and Part-B (dose expansion).
Inetetamab combined with pyrotinib and chemotherapy in the treatment of breast cancer brain metastasis: A case report.
World J Clin Cases
January 2024
Central Breast Area B, Beijing University Cancer Hospital Inner Mongolia Hospital, Hohhot 010000, Inner Mongolia Autonomous Region, China.
Background: Breast cancer brain metastasis (BCBM) is an advanced breast disease that is difficult to treat and is associated with a high risk of death. Patient prognosis is usually poor, with reduced quality of life. In this context, we report the case of a patient with HER-2-positive BCBM treated with a macromolecular mAb (inetetamab) combined with a small molecule tyrosine kinase inhibitor (TKI).
View Article and Find Full Text PDFCalcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder.
JAMA Netw Open
July 2023
Research, Education, Evaluation and Engagement Activities Center for Headache, Headache Centers of Excellence, US Department of Veterans Affairs, Orange, Connecticut.
Importance: Calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology, is also a key neuroimmune modulator. CGRP antagonists may help mitigate the hyperinflammatory response observed in patients with COVID-19; however, findings from the literature are contradictory, and to date, no study has investigated the safety and effectiveness of CGRP antagonists against COVID-19.
Objective: To evaluate the association between CGRP monoclonal antibody (mAb) treatment and risk of SARS-CoV-2 infection and sequela hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death.
Grouper cGAS is a negative regulator of STING-mediated interferon response.
Front Immunol
February 2023
College of Marine Sciences, South China Agricultural University, Guangdong Laboratory for Lingnan Modern Agriculture, Guangzhou, China.
Cyclic GMP-AMP synthase (cGAS) is one of the classical pattern recognition receptors that recognizes mainly intracytoplasmic DNA. cGAS induces type I IFN responses to the cGAS-STING signaling pathway. To investigate the roles of cGAS-STING signaling pathway in grouper, a cGAS homolog (named EccGAS) was cloned and identified from orange-spotted grouper ().
View Article and Find Full Text PDFThe natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study.
Genet Med
December 2022
Departments of Orthopaedic Surgery and Medicine, Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address:
Purpose: We report the first prospective, international, natural history study of the ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP). FOP is characterized by painful, recurrent flare-ups, and disabling, cumulative heterotopic ossification (HO) in soft tissues.
Methods: Individuals aged ≤65 years with classical FOP (ACVR1 variant) were assessed at baseline and over 36 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!